Is Vertex Stock Still a Good Buy?
Over the past ten years or so, Vertex Pharmaceuticals (NASDAQ:…
Sell
31
ILMN Quote, Financials, Valuation and Earnings
Last price:
$77.61
Seasonality move
:
8.6%
Day range:
$75.89 - $77.63
52-week range:
$68.70 - $156.66
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.81x
P/B ratio:
5.15x
Volume:
1.4M
Avg. volume:
2.3M
1-year change:
-36.56%
Market cap:
$12.2B
Revenue:
$4.4B
EPS (TTM):
-$7.68
Analysts' Opinion
-
Consensus RatingIllumina has received a consensus rating of Hold. The company's average rating is a Hold based on 7 Buy ratings, 11 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $115.55, Illumina has an estimated upside of 49.87% from its current price of $77.10.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $75.00 representing 2.72% downside risk from its current price of $77.10.
Fair Value
-
According to the consensus of 18 analysts, Illumina has 49.87% upside to fair value with a price target of $115.55 per share.
ILMN vs. S&P 500
-
Over the past 5 trading days, Illumina has overperformed the S&P 500 by 2.28% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Illumina does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Illumina revenues have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter Illumina reported revenues of $1.1B.
Earnings Growth
-
Illumina earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Illumina reported earnings per share of $1.17.
Enterprise value:
13B
EV / Invested capital:
--
Price / LTM sales:
2.81x
EV / EBIT:
--
EV / Revenue:
2.97x
PEG ratio (5yr expected):
-2.17x
EV / Free cash flow:
18.31x
Price / Operating cash flow:
17.32x
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$2.9B
Return On Assets:
-15.85%
Net Income Margin (TTM):
-27.95%
Return On Equity:
-35.09%
Return On Invested Capital:
-22.97%
Operating Margin:
17.48%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $4.6B | $4.5B | $4.4B | $1.1B | $1.1B | |
| Gross Profit | $3B | $2.7B | $2.9B | $674M | $728M | |
| Operating Income | $354M | -$238M | $584M | -$152M | $193M | |
| EBITDA | -$3.9B | -$608M | -$725M | -$40M | $283M | |
| Diluted EPS | -$28.00 | -$7.34 | -$7.68 | -$1.11 | $1.17 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $4.5B | $2.7B | $3.6B | $2.6B | $2.7B | |
| Total Assets | $7.6B | $15.2B | $12.3B | $10.1B | $6.3B | |
| Current Liabilities | $1.2B | $1.1B | $2.8B | $1.6B | $1.5B | |
| Total Liabilities | $2.9B | $4.5B | $5.7B | $4.4B | $3.9B | |
| Total Equity | $4.7B | $10.7B | $6.6B | $5.7B | $2.4B | |
| Total Debt | $1.2B | $1.7B | $2.7B | $1.5B | $2B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $392M | $478M | $837M | $224M | $364M | |
| Cash From Investing | -$591M | -$231M | -$178M | -$85M | -$48M | |
| Cash From Financing | $1B | -$1.2B | -$570M | -$27M | -$47M | |
| Free Cash Flow | $106M | $283M | $709M | $173M | $335M | |
ILMN
Sector
Market Cap
$12.2B
$34.9M
Price % of 52-Week High
49.22%
44.35%
Dividend Yield
0%
0%
Shareholder Yield
-0.19%
-0.82%
1-Year Price Total Return
-36.56%
-38.5%
Beta (5-Year)
1.376
0.738
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$75.39
200-day SMA
Sell
Level
$120.76
Bollinger Bands (100)
Sell
Level
81.51 - 136.57
Chaikin Money Flow
Buy
Level
383.2M
20-day SMA
Buy
Level
$75.16
Relative Strength Index (RSI14)
Sell
Level
46.72
ADX Line
Buy
Level
25.69
Williams %R
Neutral
Level
-21.2746
50-day SMA
Sell
Level
$83.22
MACD (12, 26)
Sell
Level
-2.38
25-day Aroon Oscillator
Sell
Level
-44
On Balance Volume
Neutral
Level
240.8M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (3.325)
Sell
CA Score
(Annual)
Level (-0.8738)
Buy
Beneish M-Score
(Annual)
Level (-4.3382)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (1.1426)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (6)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina’s high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Stock Forecast FAQ
In the current month, ILMN has received 7 Buy ratings 11 Hold ratings, and 0 Sell ratings. The ILMN average analyst price target in the past 3 months is $115.55.
-
Where Will Illumina Stock Be In 1 Year?
According to analysts, the consensus estimate is that Illumina share price will rise to $115.55 per share over the next 12 months.
-
What Do Analysts Say About Illumina?
Analysts are divided on their view about Illumina share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Illumina is a Sell and believe this share price will drop from its current level to $75.00.
-
What Is Illumina's Price Target?
The price target for Illumina over the next 1-year time period is forecast to be $115.55 according to 18 Wall Street analysts, 7 of them rate the stock a Buy, 0 rate the stock a Sell, and 11 analysts rate the stock a Hold.
-
Is ILMN A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Illumina is a Hold. 11 of 18 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of ILMN?
You can purchase shares of Illumina via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Illumina shares.
-
What Is The Illumina Share Price Today?
Illumina was last trading at $77.61 per share. This represents the most recent stock quote for Illumina. Yesterday, Illumina closed at $77.10 per share.
-
How To Buy Illumina Stock Online?
In order to purchase Illumina stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Okta Stock Finally Gaining Investor Confidence?
Given how digital transformation has proliferated, cyberattacks have also been…
Is The Trade Desk the Best Advertising Stock Now?
The worldly backdrop is now shrouded in heavy uncertainty and…
Stock Ideas
Buy
59
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
55
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 37x
Alerts
Buy
85
HIMS alert for Apr 30
Hims & Hers Health [HIMS] is down 5.48% over the past day.
Buy
54
EAT alert for Apr 30
Brinker International [EAT] is down 1.82% over the past day.
Sell
16
NSP alert for Apr 30
Insperity [NSP] is down 3.3% over the past day.
